Cerus Announces Schedule of Presentations at the 2018 AABB Annual Meeting
CONCORD, Calif.--(BUSINESS WIRE)--Oct 12, 2018--Cerus Corporation (Nasdaq: CERS) announced today its schedule of key events and presentations at the 2018 AABB Annual Meeting which is taking place in Boston on October 13 through October 16.
The AABB Annual Meeting is the largest blood banking conference of the year. Scientists and clinicians from around the world will be attending to learn about the latest developments in the industry.
Scheduled presentations of interest include the economic impact of implementing pathogen-reduced platelets at blood centers and hospitals, additional data reinforcing the clinical utility of pathogen-reduced platelets, and results from SPARC, Cerus’ European Phase 3 study of pathogen-reduced red blood cells.
“We are pleased to share with the blood banking community the latest data on the INTERCEPT Blood System, which further adds to the clinical body of evidence supporting the use of pathogen-reduction to improve the safety and availability of the blood supply,” said Dr. Richard Benjamin, Cerus’ chief medical officer.
“This year, we have 7 oral presentations that we think underscore the growing interest in pathogen-reduction and increasing awareness on the risks associated with transfusion transmitted infections,” continued Benjamin. “Between Cerus and our scientific collaborators, we will have 22 abstract presentations at AABB.”
Company representatives from Cerus will be in the exhibition areas at booth #2133.
The following is a select list of presentations of interest. All presentations are listed in Eastern Daylight Time (EDT). A full list of Cerus related abstracts can be viewed at https://intercept-usa.com/aabb2018.
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181012005075/en/
CONTACT: Cerus Corporation
Tim Lee, 925-288-6137
Investor Relations Director
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY INFECTIOUS DISEASES MEDICAL DEVICES RESEARCH OTHER SCIENCE MEDICAL SUPPLIES SCIENCE GENERAL HEALTH
SOURCE: Cerus Corporation
Copyright Business Wire 2018.
PUB: 10/12/2018 08:30 AM/DISC: 10/12/2018 08:30 AM